Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, Selcuklu SD, Weinhold N, Bouvier N, Huberman KH, Bhanot U, Chevinsky MS, Patel P, Pinciroli P, Won HH, You D, Viale A, Lee W, Hakimi AA, Berger MF, Socci ND, Cheng EH, Knox J, Voss MH, Voi M, Motzer RJ. Hsieh JJ, et al. Among authors: redzematovic a. Eur Urol. 2017 Mar;71(3):405-414. doi: 10.1016/j.eururo.2016.10.007. Epub 2016 Oct 15. Eur Urol. 2017. PMID: 27751729 Free PMC article.
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
Voss MH, Molina AM, Chen YB, Woo KM, Chaim JL, Coskey DT, Redzematovic A, Wang P, Lee W, Selcuklu SD, Lee CH, Berger MF, Tickoo SK, Reuter VE, Patil S, Hsieh JJ, Motzer RJ, Feldman DR. Voss MH, et al. Among authors: redzematovic a. J Clin Oncol. 2016 Nov 10;34(32):3846-3853. doi: 10.1200/JCO.2016.67.9084. J Clin Oncol. 2016. PMID: 27601542 Free PMC article. Clinical Trial.
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Tennenbaum DM, Manley BJ, Zabor E, Becerra MF, Carlo MI, Casuscelli J, Redzematovic A, Khan N, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Benfante NE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA. Tennenbaum DM, et al. Among authors: redzematovic a. Urol Oncol. 2017 Aug;35(8):532.e7-532.e13. doi: 10.1016/j.urolonc.2017.03.015. Epub 2017 Apr 10. Urol Oncol. 2017. PMID: 28408295 Free PMC article.
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ, Zabor EC, Casuscelli J, Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Ogawa S, Arcila ME, Voss MH, Feldman DR, Coleman JA, Reuter VE, Motzer RJ, Russo P, Hsieh JJ, Hakimi AA. Manley BJ, et al. Among authors: redzematovic a. Eur Urol Focus. 2017 Oct;3(4-5):421-427. doi: 10.1016/j.euf.2016.06.015. Epub 2016 Jul 16. Eur Urol Focus. 2017. PMID: 28753773 Free PMC article.
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, Fabbri N, Healey JH, Boland PJ, Chawla M, Durack JC, Lee CH, Coleman JA, Russo P, Hakimi AA, Cheng EH, Hsieh JJ. Dong Y, et al. Among authors: redzematovic a. Eur Urol Focus. 2017 Dec;3(6):590-598. doi: 10.1016/j.euf.2016.08.005. Epub 2016 Aug 25. Eur Urol Focus. 2017. PMID: 28753786 Free PMC article.
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA. Casuscelli J, et al. Among authors: redzematovic a. Eur Urol Focus. 2019 Jul;5(4):642-649. doi: 10.1016/j.euf.2017.09.008. Epub 2017 Sep 24. Eur Urol Focus. 2019. PMID: 28951115 Free PMC article.
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, Socci N, Carlo MI, Lee CH, Voss MH, Feldman DR, Motzer RJ, Coleman JA, Russo P, Cheng EH, Hakimi AA, Hsieh JJ. Becerra MF, et al. Among authors: redzematovic a. Eur Urol Focus. 2018 Dec;4(6):986-994. doi: 10.1016/j.euf.2017.09.016. Epub 2017 Oct 20. Eur Urol Focus. 2018. PMID: 29066084 Free PMC article.
PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.
Voss MH, Chen D, Reising A, Marker M, Shi J, Xu J, Ostrovnaya I, Seshan VE, Redzematovic A, Chen YB, Patel P, Han X, Hsieh JJ, Hakimi AA, Motzer RJ. Voss MH, et al. Among authors: redzematovic a. Clin Cancer Res. 2019 Jan 15;25(2):506-514. doi: 10.1158/1078-0432.CCR-18-1833. Epub 2018 Oct 16. Clin Cancer Res. 2019. PMID: 30327302 Clinical Trial.
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.
Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale RG, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Motzer RJ, Voss MH. Ged Y, et al. Among authors: redzematovic a. Clin Genitourin Cancer. 2019 Jun;17(3):e678-e688. doi: 10.1016/j.clgc.2019.03.018. Epub 2019 Apr 1. Clin Genitourin Cancer. 2019. PMID: 31036466 Free PMC article.
18 results